COMy 2021 | Moving forward: bringing CAR-T therapy to a frontline setting in myeloma
The FDA approval of idecabtagene-vicleucel for the treatment of relapsed/refractory (R/R) multiple myeloma represents the first cell-based gene therapy approval in myeloma. Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the ongoing growth of the CAR-T field and how to improve its success. Outstanding response rates have been achieved using CAR T-cell therapy in late-stage disease, and thus, bringing it to an earlier line has the potential to elicit deeper and more durable responses. Prof. Martin talks on the possibility of CAR-T therapy replacing autologous transplant in the frontline setting and the need for investigations into maintenance therapy to support this development. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
